Aristo Bio-Tech & Lifescience Ltd
Chemicals & Petrochemicals | Small Cap
Aristo Bio-Tech & Lifescience Ltd demonstrates a mixed financial performance. The company shows strong solvency and growth, driven by effective management of debt and impressive increases in revenue, operating profit, and EPS. Profitability metrics are also robust, supported by healthy gross profit and operating margins. However, liquidity is a concern, with ratios indicating potential difficulties in meeting short-term obligations. While efficiency ratios are generally average, there are notable strengths in asset turnover. The company's financial ratios reveal some weaknesses in earnings per share and book value per share, despite adequate capital expenditure. Overall, Aristo Bio-Tech showcases solid financial health, but needs to improve its liquidity position and financial metrics to ensure long-term stability and growth.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsUndervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio3.60
- Profitability Ratio9.60
- Efficiency Ratio6.33
- Coverage Ratio8.80
- Solvency Ratio10.00
- Liquidity Ratio4.26
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Aristo Bio-Tech & Lifescience Ltd demonstrates a mixed financial performance. The company shows strong solvency and growth, driven by effective management of debt and impressive increases in revenue, operating profit, and EPS. Profitability metrics are also robust, supported by healthy gross profit and operating margins. However, liquidity is a concern, with ratios indicating potential difficulties in meeting short-term obligations. While efficiency ratios are generally average, there are notable strengths in asset turnover. The company's financial ratios reveal some weaknesses in earnings per share and book value per share, despite adequate capital expenditure. Overall, Aristo Bio-Tech showcases solid financial health, but needs to improve its liquidity position and financial metrics to ensure long-term stability and growth.
Overall Valuation Score
P/E RATIO (TTM)
21.42
Industry Median
22.59
Small Cap Median
21.70
P/E RATIO
19.45
P/B RATIO
1.90
Industry Median
1.76
Small Cap Median
1.77
P/S RATIO
0.25
Industry Median
0.89
Small Cap Median
0.88
Others
PEG RATIO
0.61
EV/EBITDA RATIO
8.49
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹115.9 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates strong growth across various metrics. The revenue growth rate is impressive, indicating successful expansion of sales. The operating profit growth rate is also robust, reflecting improved operational efficiency. Earnings per share (EPS) growth is significant, showing enhanced profitability for shareholders. The asset growth rate is healthy, reflecting strategic investments and expansion. The net income growth rate is also substantial, indicating improved overall profitability. These factors collectively suggest that the company is experiencing strong and sustainable growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -0.6 | 31.33 | 12.39 | 29.8 | 14.47 |
| Operating Profit Growth Rate | 25 | 80 | -11.11 | 12.5 | 77.78 |
| Earnings Per Share (EPS) Growth | -2.78 | 149.05 | 9.56 | 4.01 | 77.01 |
| Asset Growth Rate | -4.94 | 29.87 | 27 | 11.02 | 9.93 |
| Net Income Growth Rate | 0 | 300 | 0 | 0 | 75 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios reveal certain weaknesses. The adjusted earnings per share and book value per share are low, indicating potential concerns about profitability and shareholder value. The cash earnings per share is also relatively low. However, capital expenditures are adequate, reflecting ongoing investments in the company's growth and infrastructure. These factors collectively suggest that the company needs to improve its earnings and shareholder value to enhance its financial performance.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2 | 5.71 | 5.71 | 5.71 | 10 |
| Cash Earnings Per Share (Cash EPS) | 4 | 8.57 | 8.57 | 10 | 14.29 |
| Book Value Per Share | 30 | 42.86 | 48.57 | 54.29 | 64.29 |
| Dividend Per Share (DPS) | 0 | 0.26 | 0.4 | 0.48 | 0.63 |
| Capital Expenditures (CapEx) | 3.1 | 2.5 | 6.5 | 4.9 | 3 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are generally strong. The gross profit margin is healthy, indicating effective cost management. The return on capital employed (ROCE) is also robust, reflecting efficient use of capital to generate profits. The return on equity (ROE) is substantial, showing good returns for shareholders. The return on assets (ROA) is moderate, suggesting adequate asset utilization. The operating margin is healthy, reflecting efficient operational performance. The net margin is also robust, indicating good overall profitability. These factors collectively suggest that the company is effectively managing its profitability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 2.41 | 3.21 | 2.45 | 1.89 | 3.57 |
| Return on Capital Employed (ROCE) | 11 | 16 | 13 | 12 | 20 |
| Return on Equity (ROE) | 6.67 | 13.33 | 11.76 | 10.53 | 15.56 |
| Return on Assets (ROA) | 6.49 | 9 | 6.3 | 6.38 | 10.32 |
| Operating Margin | 3.01 | 4.13 | 3.27 | 2.83 | 4.4 |
| Net Margin | 0.6 | 1.83 | 1.63 | 1.26 | 1.92 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. The fixed asset turnover ratio is strong, indicating effective utilization of fixed assets to generate revenue. However, the inventory turnover ratio and receivables turnover ratio are average, suggesting there may be room for improvement in managing inventory and collecting receivables. The days sales in inventory ratio is also average, indicating that the company holds inventory for a moderate period. The receivable days are slightly elevated, suggesting potential challenges in collecting payments promptly. The capital turnover ratio is average, reflecting moderate efficiency in using capital to generate revenue.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 11.86 | 13.62 | 11.14 | 13.25 | 15.17 |
| Inventory Turnover Ratio | 5.79 | 7.67 | 6.7 | 7.17 | 6.38 |
| Receivables Turnover Ratio | 5.03 | 5.59 | 4.8 | 5.63 | 6.56 |
| Days Sales in Inventory Ratio | 63.04 | 47.59 | 54.48 | 50.91 | 57.21 |
| Receivable Days | 72.56 | 65.3 | 76.04 | 64.83 | 55.64 |
| Capital Turnover Ratio | 6.36 | 5.43 | 5.57 | 6.97 | 6.92 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios indicate a strong ability to meet its interest and dividend obligations. The interest coverage ratio suggests that the company can comfortably cover its interest expenses with its earnings. The equity dividend coverage ratio is also high, indicating that the company has ample earnings to cover its dividend payments. These factors collectively suggest that the company has a strong capacity to service its debt and provide returns to its shareholders.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 2 | 2.67 | 3.5 | 3.5 | 3.5 |
| Equity Dividend Coverage Ratio | 20 | 14.29 | 12.5 | 16.67 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, indicating a solid financial foundation. A low debt ratio and debt-to-equity ratio suggest conservative use of leverage. A high equity ratio further supports the company's financial stability. The low debt-to-asset ratio confirms that a small portion of the company's assets are financed by debt. These factors collectively suggest that the company has a strong capacity to meet its long-term obligations and manage its financial risks effectively.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.43 | 0.25 | 0.23 | 0.17 | 0.14 |
| Debt to Equity Ratio | 0.75 | 0.33 | 0.3 | 0.2 | 0.16 |
| Equity Ratio | 0.57 | 0.75 | 0.77 | 0.83 | 0.86 |
| Debt To Asset Ratio | 0.14 | 0.1 | 0.08 | 0.05 | 0.05 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position reveals certain vulnerabilities. While the quick ratio suggests an ability to meet immediate liabilities, this is offset by a low cash ratio, indicating limited availability of liquid assets. The current ratio is below the ideal threshold, suggesting potential difficulties in covering short-term obligations. The operating cash flow ratio needs improvement to ensure alignment with short-term funding needs. These factors collectively indicate that the company may face liquidity challenges, requiring careful management of working capital.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.4 | 1.26 | 1.23 | 1.27 |
| Quick Ratio | 0.76 | 0.88 | 0.79 | 0.74 | 0.66 |
| Cash Ratio | 0 | 0.03 | 0.01 | 0.01 | 0.03 |
| Operating Cash Flow Ratio | 0.14 | -0.05 | 0.1 | 0.11 | 0.08 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Aristo Bio-Tech & Lifescience Ltd | 7.93 | 19.45 | Undervalued | 16.00 | 10.55 | 7.00 |
| 2 | Ambey Laboratories Ltd | 7.08 | 19.30 | Neutral | 10.00 | 1.92 | N/A |
| 3 | Crop Life Science Ltd | 6.87 | 11.37 | Neutral | 18.00 | 4.08 | 6.00 |
The management effectiveness of Aristo Bio-Tech & Lifescience Ltd shows a mixed performance. The company exhibits strong sales growth and increasing dividend payouts, indicating positive financial development. However, there are concerns regarding profitability and capital efficiency, with inconsistent operating profit margins and a low ROCE. Despite stable promoter holding, the fluctuations in financial performance suggest areas where management could enhance operational efficiency and capital allocation.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth TTM | 30% | Strong sales growth indicates market competitiveness. |
| Dividend Payout (Mar 2025) | 8% | Increasing dividend payout suggests management's confidence in future earnings. | |
| CONS | OPM (Mar 2025) | 1% | Low OPM raises concerns about operational efficiency. |
| ROCE (Mar 2024) | 13% | Low ROCE signals inefficient capital allocation. |
Financial Performance & Growth
Aristo Bio-Tech & Lifescience Ltd demonstrates mixed financial performance. Sales have grown, but profitability metrics show inconsistencies.
PROS: Strong Sales Growth The company has demonstrated strong sales growth, especially in the recent term. The compounded sales growth shows a positive trend, with the TTM at 30%.
| Metric | 3 Years | TTM |
|---|---|---|
| Compounded Sales Growth (%) | 24% | 30% |
CONS: Fluctuating Profitability Operating Profit Margin (OPM) has remained relatively low and fluctuated over the quarters.
| Metric | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| OPM % | 1% | 4% | 4% | 4% | 3% | 4% | 1% |
Capital Efficiency & Returns
The company's capital efficiency and returns present a mixed picture. While Return on Equity (ROE) has been maintained at a reasonable level, there are concerns about the Return on Capital Employed (ROCE).
CONS: Declining ROCE ROCE % has shown a declining trend over the years.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| ROCE % | 24% | 14% | 11% | 11% | 16% | 13% | 13% |
Financial Health & Prudence
Aristo Bio-Tech & Lifescience exhibits a stable financial health profile with controlled debt and improving dividend payouts.
PROS: Increasing Dividend Payout The dividend payout ratio has improved, indicating a greater willingness to share profits with shareholders.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Dividend Payout % | 5% | 7% | 8% |
Strategic & Operational Indicators
Aristo Bio-Tech & Lifescience shows mixed performance in strategic and operational aspects.
CONS: Inefficient Cash Conversion Cycle The Cash Conversion Cycle (CCC) has fluctuated, indicating some inefficiency in working capital management.
| Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| CCC (Days) | 16 | 11 | 23 | 18 | 61 | 56 | 46 | 48 | 38 | 26 |
The risk assessment for Aristo Bio-Tech & Lifescience Ltd indicates moderate risk. The company's trends in sales growth and profitability suggest some operational risks. The absence of data on off-balance sheet exposures and contingent liabilities limits a full assessment, suggesting a need for further investigation into these areas.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposure quantification.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation.
Segment performance volatility
There is no specific data available on segment performance volatility.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe